Gwangdong Pharmaceutical's Presbyopia Eye Drop "Ubegye" Wins U.S. FDA Approval...Domestic Review Underway
Product approval application submitted to MFDS
Gwangdong Pharmaceutical announced on the 13th that Ubegye, a presbyopia treatment for which it holds exclusive distribution rights in Korea, has obtained approval from the U.S. Food and Drug Administration (FDA).
Ubegye is an ophthalmic solution developed by the global biotech company Tenpoint Therapeutics. It is a combination drug that combines 2.75% carbachol and 0.1% brimonidine tartrate. Its mechanism of action involves inducing a pinhole effect through pupil constriction, thereby improving near visual acuity and depth of focus. When administered once daily, its effects appear approximately 30 minutes after instillation and last for up to 10 hours.
This approval was based on the results of Phase 3 clinical trials (BRIO I and II) conducted in more than 800 patients. In the trials, uncorrected near visual acuity in both eyes improved in a statistically significant manner, and no deterioration in distance vision was observed. Long-term 12‑month studies also confirmed safety and tolerability.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Gwangdong Pharmaceutical secured the domestic distribution rights by signing an exclusive license agreement for the Asian region with Hong Kong–based Jiaoker in 2024. The company applied for product approval to the Ministry of Food and Drug Safety in September last year, and the review is currently underway. The FDA approval is expected to be used as a reference indicator in the domestic approval review process.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.